Basic 34,484 34,503 34,422 34,191
Diluted 34,703 34,503 34,653 34,435
Reconciliation Between Reported (GAAP) and Adjusted Net Income (Loss)
(In thousands, except per share data)
(Unaudited)
Three Months Ended
Dec. 31, Dec. 31,
2006 2005
Reported Net Income $5,045 $(35,713)
Severance Costs 5,229 --
Asset Impairment 1,000 9,178
Investment Gain (3,190) --
Loss from Discontinued Operations -- 39,566
Estimated Tax on Adjustments (1,185) (18,128)
Adjusted Net Income (Loss) (non-GAAP measure) $6,899 $(5,097)
Diluted Earnings (Loss) Per Share:
Reported $0.15 $(1.04)
Adjusted (non-GAAP measure) $0.20 $(0.15)
Twelve Months Ended
Dec. 31, Dec. 31,
2006 2005
Reported Net Income $6,741 $(15,309)
Severance Costs 12,373 --
Write-off of Accounts Receivable
Relating to Invalid Customer Deductions 9,965 --
Arbitration Settlement 1,502 --
Asset Impairment
'/>"/>
| SOURCE Par Pharmaceutical Companies, Inc. Copyright©2007 PR Newswire. All rights reserved |